Intellia Therapeutics, Inc.NTLANASDAQ

Revenue (LTM)

$68M

+16.9% YoY

Net Income (LTM)

$-413M

+20.5% YoY

Free Cash Flow

$-355M

Revenue CAGR (5Y)

+3.1%

Marginsdeclining

FCF($0.4B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	33	52↑57.7%	36↓30.4%	58↑59.6%	68↑16.9%
Gross Profit	26	45↑70.3%	27↓38.7%	48↑74.3%	52↑8.7%
Operating Income	-268	-458↓71.1%	-515↓12.5%	-534↓3.7%	-441↑17.5%
Net Income	-268	-474↓77.0%	-481↓1.5%	-519↓7.9%	-413↑20.5%
EBITDA	-261	-451↓72.7%	-506↓12.4%	-524↓3.5%	-397↑24.3%
EPS Diluted	-3.78	-6.16↓63.0%	-5.42↑12.0%	-5.25↑3.1%	-3.81↑27.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	123	524↑324.2%	227↓56.7%	189↓16.6%	155↓17.8%
Total Current Assets	769	1,217↑58.2%	998↓18.0%	640↓35.9%	528↓17.5%
Total Assets	1,294	1,520↑17.4%	1,301↓14.4%	1,191↓8.5%	842↓29.3%
Total Current Liabilities	126	127↑0.6%	115↓9.0%	111↓3.8%	104↓6.3%
Total Liabilities	254	285↑11.9%	251↓11.9%	319↑27.2%	171↓46.5%
Total Equity	1,040	1,236↑18.8%	1,050↓15.0%	872↓17.0%	671↓23.0%
Total Debt	74	131↑76.6%	115↓11.7%	210↑82.2%	93↓55.6%
Net Debt	-49	-393↓695.4%	-111↑71.6%	21↑118.9%	-62↓395.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-225	-333↓48.1%	-394↓18.2%	-349↑11.5%	-349↓0.0%
Capital Expenditure	-13	-58↓357.7%	-14↑76.0%	-6↑58.7%	-6↓0.0%
Free Cash Flow	-238	-392↓64.7%	-408↓4.2%	-355↑13.1%	-355↓0.0%
Stock-Based Comp	47	91↑94.4%	134↑46.7%	154↑15.1%	154↓0.0%
Net Change in Cash	-39	410↑1148.0%	-295↓172.0%	-38↑87.3%	-38↓0.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance